Literature DB >> 9490946

Pancreatic enhancement and pulse sequence analysis using low-dose mangafodipir trisodium.

W W Mayo-Smith1, W Schima, S Saini, G J Slater, E G McFarland.   

Abstract

OBJECTIVE: The purpose of this study was to evaluate pancreatic enhancement with low-dose mangafodipir trisodium (5 mumol/kg) using three different T1-weighted pulse sequences. SUBJECTS AND METHODS: Fifteen patients, six of whom had proven focal pancreatic tumors, underwent T1-weighted gradient-recalled echo imaging, spin-echo imaging, and fat-suppressed spin-echo imaging before and 30 min after injection of 5 mumol/kg of mangafodipir trisodium. Region-of-interest measurements were obtained in the pancreas before and after contrast enhancement. Signal-to-noise ratios were calculated in all 15 patients. Contrast-to-noise ratios were calculated in the six patients with pancreatic tumors.
RESULTS: The signal-to-noise ratios of the pancreas increased after injection of mangafodipir trisodium on all three T1-weighted pulse sequences (p < .001). Enhanced fat-suppressed sequences (29 +/- 7.7) and gradient-recalled echo sequences (29 +/- 9.6) had the highest signal-to-noise ratios. Contrast-to-noise ratios between normal pancreatic tissue and pancreatic tumor also increased after contrast administration (p < .05) and were highest on the fat-suppressed (-9.6 +/- 4.0) pulse sequence.
CONCLUSION: Mangafodipir trisodium produced marked pancreatic enhancement at a dose of 5 mumol/kg for all three T1-weighted pulse sequences. The enhanced T1-weighted spin-echo fat-suppressed sequence showed the highest signal-to-noise and contrast-to-noise ratios.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9490946     DOI: 10.2214/ajr.170.3.9490946

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  6 in total

Review 1.  The role of transabdominal ultrasonography, helical computed tomography, and magnetic resonance cholangiopancreatography in diagnosis and management of pancreatic disease.

Authors:  I D Norton; J E Clain
Journal:  Curr Gastroenterol Rep       Date:  2000-04

Review 2.  Magnetic resonance imaging of pancreatic adenocarcinoma.

Authors:  L M Fayad; D G Mitchell
Journal:  Int J Gastrointest Cancer       Date:  2001

Review 3.  Safety of MR liver specific contrast media.

Authors:  Marie-France Bellin; Judith A W Webb; Aart J Van Der Molen; Henrik S Thomsen; Sameh K Morcos
Journal:  Eur Radiol       Date:  2004-12-31       Impact factor: 5.315

Review 4.  Advances in imaging for pancreatic disease.

Authors:  Chiara Del Frate; Romeo Zanardi; Koenraad Mortele; Pablo R Ros
Journal:  Curr Gastroenterol Rep       Date:  2002-04

Review 5.  Pancreatic adenocarcinoma.

Authors:  Wolfgang Schima; Ahmed Ba-Ssalamah; Claus Kölblinger; Christiane Kulinna-Cosentini; Andreas Puespoek; Peter Götzinger
Journal:  Eur Radiol       Date:  2006-10-05       Impact factor: 5.315

6.  Mangafodipir trisodium-enhanced MR imaging of pancreatic disease.

Authors:  Piero Boraschi; Francescamaria Donati; Roberto Gigoni; Davide Caramella; Ugo Boggi; Fabio Falaschi; Carlo Bartolozzi
Journal:  Eur Radiol       Date:  2006-01-19       Impact factor: 5.315

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.